title: Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine.
abstract: Persistence of antibodies after a single dose of Tdap vaccine (tetanus, diphtheria, and 5-component acellular pertussis vaccine) was evaluated in a follow-up study of adolescents (N=324) and adults (N=644) who had received Tdap in earlier clinical trials. Outcome measures were seroprotection (tetanus and diphtheria) or seropositivity (pertussis) and geometric mean concentrations. Humoral immune responses to all antigens were robust 1 month after initial immunization, decreased at subsequent measurements, but continued to exceed pre-immunization levels 1, 3, 5, and 10 years later. Protective levels of diphtheria and tetanus antitoxin persisted in 99.3% of adolescents 10 years after a booster dose of Tdap. Seropositivity to 1 or more pertussis antigens also persisted in most adolescents for 10 years. Although tetanus antitoxin responses were similar in adults to those observed in adolescents, diphtheria antitoxin titers were lower, reflecting the fact that a smaller proportion of adults had received diphtheria toxoid in the previous 10 years compared to adolescents. These data will contribute to the selection of the optimal interval for repeat doses of Tdap.
authors.affiliation: Sanofi Pasteur Limited, Toronto, Ontario M2R 3T4, Canada. miggi.tomovici@sanofipasteur.com
authors.forename: A
authors.initials: A
authors.lastname: Tomovici
authors.forename: L
authors.initials: L
authors.lastname: Barreto
authors.forename: P
authors.initials: P
authors.lastname: Zickler
authors.forename: W
authors.initials: W
authors.lastname: Meekison
authors.forename: F
authors.initials: F
authors.lastname: Noya
authors.forename: T
authors.initials: T
authors.lastname: Voloshen
authors.forename: P
authors.initials: P
authors.lastname: Lavigne
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology; D002648:Child; D004165:Diphtheria / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007110:Immunity, Active; D056724:Immunity, Humoral; D007117:Immunization, Secondary; D008297:Male; D008875:Middle Aged; D013742:Tetanus / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D017778:Vaccines, Combined; D014917:Whooping Cough / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*
chemical_list: D000907:Antibodies, Bacterial; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D017778:Vaccines, Combined